How to administer intravenous (IV) albumin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Administration of Intravenous Albumin

Intravenous albumin should be administered by slow infusion, with rates not exceeding 2 mL per minute to prevent circulatory overload and pulmonary edema, particularly in patients with normal blood volumes. 1

General Administration Guidelines

Route and Preparation

  • Always administer albumin by intravenous infusion 1
  • Can be administered either undiluted or diluted in:
    • 0.9% Sodium Chloride
    • 5% Dextrose in Water
  • For patients requiring sodium restriction, administer undiluted or diluted in sodium-free solutions (e.g., 5% Dextrose in Water) 1

Administration Rate

  • Standard rate: Not exceeding 2 mL per minute for hypoproteinemic patients 1
  • Slower rates may be necessary for patients at risk of circulatory overload
  • Always monitor patients carefully during administration to prevent circulatory overload 1

Specific Clinical Scenarios and Dosing

Cirrhosis with Large-Volume Paracentesis (>5L)

  • Dose: 6-8 g albumin per liter of ascitic fluid removed 2
  • Timing: Administer during or immediately after paracentesis 3
  • For patients with acute-on-chronic liver failure: Administer 6-8 g/L regardless of amount of ascites removed 3

Spontaneous Bacterial Peritonitis (SBP)

  • Standard dose: 1.5 g/kg on day 1, followed by 1 g/kg on day 3 3, 2
  • Alternative lower dose regimen: 10 g/day for days 1-3 (has shown efficacy in smaller studies) 3
  • Patients with jaundice (bilirubin >4 mg/dL) and/or AKI at baseline are most likely to benefit 3

Hypovolemic Shock

  • Dose and infusion speed should be adapted to individual patient response 1
  • Used as second-line therapy after crystalloids 4

Compatibility and Contraindications

Compatible with:

  • Whole blood and packed red cells
  • Standard carbohydrate and electrolyte solutions for IV use 1

Incompatible with:

  • Protein hydrolysates
  • Amino acid solutions
  • Solutions containing alcohol 1

Monitoring and Precautions

During Administration:

  • Monitor for signs of circulatory overload:
    • Increased blood pressure
    • Distended neck veins
    • Pulmonary edema
    • Dyspnea 1

Special Considerations:

  • In dehydrated patients, albumin must be given with or followed by additional fluids 1
  • In hemorrhage, supplement albumin with whole blood transfusion to prevent hemodilution 1
  • Rapid blood pressure rise may occur, requiring careful observation for bleeding from previously undetected vessels 1

Common Pitfalls and Caveats

  1. Inappropriate Use: Albumin is not recommended for routine treatment of hypoalbuminemia alone or as nutritional support 3, 2

  2. Excessive Infusion Rate: Administering too quickly can precipitate circulatory embarrassment and pulmonary edema 1

  3. Overuse in Non-Indicated Conditions: Evidence does not support routine use in:

    • Most ICU patients (excluding specific indications)
    • Infections other than SBP
    • Correction of hypoalbuminemia without specific clinical indications 3
  4. Adverse Events: Monitor for potential complications including:

    • Fluid overload
    • Pulmonary edema
    • Hypotension/tachycardia
    • Nausea/vomiting
    • Rigors, pyrexia, rash/pruritus 3

By following these evidence-based administration guidelines, clinicians can optimize the therapeutic benefits of intravenous albumin while minimizing potential risks and complications.

References

Guideline

Albumin Replacement Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Albumin: a comprehensive review and practical guideline for clinical use.

European journal of clinical pharmacology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.